- Home
- AEON vs BOLD Comparison
AEON vs BOLD Comparison
Compare AEON & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEON | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 25.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | AEON | BOLD |
|---|---|---|
| Price | $1.09 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.20 | $4.00 |
| AVG Volume (30 Days) | 85.6K | ★ 139.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 90.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.96 |
| 52 Week High | $1.45 | $1.83 |
Technical Indicators
Market Signals| Indicator | AEON | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 44.71 |
| Support Level | $0.67 | $1.10 |
| Resistance Level | $1.10 | $1.19 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.13 | 40.00 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.